Core Viewpoint - A class action lawsuit has been filed against Geron Corporation and certain officers for alleged violations of federal securities laws during the Class Period from February 28, 2024, to February 25, 2025, seeking damages for investors who acquired Geron securities during this time [1]. Company Overview - Geron Corporation is a late-stage clinical biopharmaceutical company focused on developing therapeutics for cancer and chronic degenerative diseases, with its sole product candidate being RYTELO (imetelstat), a telomerase inhibitor aimed at treating low- to intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis [4]. - RYTELO was commercially launched in June 2024 after receiving FDA approval for treating adult patients with lower-risk MDS who are transfusion-dependent and have not responded to or are ineligible for erythropoiesis-stimulating agents [5]. Allegations and Financial Performance - The lawsuit alleges that throughout the Class Period, Geron made materially false and misleading statements regarding its business and prospects, including the potential profitability of RYTELO and the company's ability to meet the unmet needs in the market [6]. - On February 26, 2025, Geron reported Q4 2024 earnings per share of -$0.04 and revenue of $47.54 million, significantly below analyst projections of -$0.02 to -$0.03 EPS and $61.93 million in revenue [7]. - Following the disappointing financial results, Geron's CEO indicated that the company had observed flat revenue trends for RYTELO, attributing this to seasonality, competition, and a lack of awareness among healthcare providers [8]. Market Reaction - After the announcement of the Q4 results, Geron's stock price fell by $0.76 per share, or 32.06%, closing at $1.61 per share on February 26, 2025 [9].

Core Viewpoint - Securities class action lawsuits have been filed against Geron Corporation for allegedly misleading investors regarding its revenue outlook and product performance during the specified class period from February 28, 2024, to February 25, 2025 [1][2]. Allegations Against Defendants - Defendants allegedly created a false impression of possessing reliable information about Geron's revenue outlook while downplaying risks from seasonality and macroeconomic factors [2]. - Reports regarding the launch success and growth potential of Geron's primary product, RYTELO, were claimed to be overly optimistic and did not reflect the reality of market conditions and competition [2]. - RYTELO reportedly lacked market awareness, hindering Geron's ability to meet the unmet need for the drug among first-line patients and those outside academic settings [2]. - Statements made by the defendants regarding the company's business and prospects were claimed to be materially false and misleading [2]. Lead Plaintiff Process - Investors in Geron have until May 12, 2025, to seek appointment as a lead plaintiff representative for the class, or they may choose to remain absent class members [3]. - The lead plaintiff will represent all class members in directing the litigation and will select counsel to represent the class [3]. Firm Background - Kessler Topaz Meltzer & Check, LLP has a reputation for prosecuting class actions and has recovered billions for victims of corporate misconduct [4].

Core Viewpoint - Geron Corporation is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives misled investors regarding the performance and market potential of its primary product, Rytelo [1][3]. Company Overview - Geron Corporation is a commercial-stage biopharmaceutical company focused on developing therapeutic products for oncology, with its main product being a telomerase inhibitor called imetelstat, marketed as Rytelo [2]. Allegations of the Lawsuit - The lawsuit alleges that Geron and its executives made false or misleading statements about the company's revenue outlook and growth potential, downplaying risks associated with seasonality and macroeconomic factors [3]. - It is claimed that the reported success of Rytelo's launch was overstated, as actual market conditions, including competition and the need for ongoing monitoring, significantly impacted patient adoption [3]. - The lawsuit further contends that Rytelo lacked sufficient market awareness, hindering Geron's ability to meet the unmet medical needs, particularly among first-line patients [3]. Financial Impact - Following the announcement of its fourth-quarter financial results for fiscal year 2024 on February 26, 2025, which revealed stagnant growth for Rytelo, Geron's stock price dropped by over 32% [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Geron Corporation due to alleged violations of federal securities laws, encouraging affected investors to come forward [2][4]. Group 1: Legal Investigation and Class Action - The firm is reminding investors of the May 12, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against Geron [2]. - The complaint alleges that Geron and its executives made false and misleading statements regarding the company's drug Rytelo, downplaying risks associated with its monitoring requirements and competition [4]. - Investors who suffered losses exceeding $100,000 in Geron between February 28, 2024, and February 25, 2025, are encouraged to contact the firm for legal options [1]. Group 2: Financial Performance and Stock Impact - On February 26, 2025, Geron announced its fourth-quarter financial results for fiscal 2024, revealing that Rytelo's growth had flattened due to seasonality, competition, and lack of awareness [5]. - Following the announcement, Geron's stock price plummeted from $2.37 per share on February 25, 2025, to $1.61 per share on February 26, 2025, marking a decline of approximately 32.07% in one day [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Geron Corporation due to alleged violations of federal securities laws, particularly concerning misleading statements about the company's drug Rytelo and its market performance [3][4]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses in Geron to contact them, highlighting a deadline of May 12, 2025, to seek the role of lead plaintiff in a federal securities class action [1][6]. - The firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [2]. Group 2: Allegations Against Geron - The complaint against Geron alleges that the company and its executives made false and misleading statements regarding their ability to meet market needs and execute their commercial plans, while downplaying risks associated with Rytelo [3]. - Geron reported that Rytelo's growth had flattened, attributing this to seasonality, competition, lack of awareness, and monitoring requirements [4]. Group 3: Stock Price Impact - Following the announcement of Rytelo's diminished growth, Geron's stock price fell from $2.37 per share on February 25, 2025, to $1.61 per share on February 26, 2025, marking a decline of approximately 32.07% in one day [5].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Geron Corporation securities between June 7, 2024, and February 25, 2025, alleging misleading statements regarding the company's revenue outlook and growth potential [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Geron Corporation made false and misleading statements about its projected revenue and growth, downplaying risks associated with seasonality and macroeconomic factors [5]. - It is alleged that Geron's reports on the launch success of Rytelo, a telomerase inhibitor, did not accurately reflect the challenges faced in the market, including competition and the need for ongoing monitoring [5]. - The lawsuit indicates that when the true situation became known, investors suffered damages due to the misleading information provided by Geron [5]. Group 2: Class Action Participation - Investors who purchased Geron securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the law firm directly for more information [3][6]. - A lead plaintiff is needed to represent the class, and interested parties must file their motion by May 12, 2025 [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in representing investor rights [4].

Core Viewpoint - Geron Corporation is facing a class action securities lawsuit due to alleged securities fraud related to the performance and market expectations of its drug Rytelo (imetelstat) between June 7, 2024, and February 25, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who were negatively impacted by the defendants' misleading statements regarding Rytelo's launch and growth potential [1][2]. - Defendants allegedly downplayed risks associated with Rytelo, including the burden of weekly monitoring and competition, while expressing confidence in the drug's market potential [2]. - Following the announcement of Geron's fourth-quarter financial results for fiscal 2024, which revealed stagnant growth for Rytelo, the company's stock price plummeted approximately 32.07%, from $2.37 to $1.61 per share in one day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified period have until May 12, 2025, to request appointment as lead plaintiff in the lawsuit [3]. - Participation in the lawsuit does not require any out-of-pocket costs for class members, and they may be entitled to compensation without financial obligation [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - A class action lawsuit has been filed against Geron Corporation for alleged violations of federal securities laws, specifically regarding misleading statements about its revenue outlook and growth potential [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Geron provided false and misleading information to investors, creating an overly optimistic view of the projected revenue and growth related to the launch of Rytelo [2]. - It is alleged that Geron did not disclose that Rytelo lacked necessary patient awareness, which hindered the company's ability to meet the claimed significant unmet need for the drug [2]. Group 2: Investor Participation - Shareholders who purchased Geron's securities between June 7, 2024, and February 25, 2025, are encouraged to contact the DJS Law Group to participate in the class action lawsuit before May 12, 2025 [1][3].

Company Performance - TJX Companies Inc reported better-than-expected fourth-quarter FY25 earnings, with sales remaining flat year-on-year at $16.4 billion, surpassing analyst consensus of $16.20 billion [2] - Overall comparable store sales increased by 5%, driven by a rise in customer transactions, and adjusted EPS was $1.23, beating the consensus estimate of $1.16 [2] Stock Movements - Enveric Biosciences, Inc. shares surged 116% to $2.54 following the announcement of promising results for its non-hallucinogenic psychedelic compounds [8] - Mullen Automotive, Inc. shares rose 59% to $3.72 after its vehicles were added to a government purchasing contract [8] - Porch Group, Inc. shares increased by 80% to $6.80 after reporting fourth-quarter financial results [8] - Flywire Corporation shares dropped 40% to $10.67 due to worse-than-expected fourth-quarter results [8] - AppLovin Corporation shares fell 17% to $311.57 amid new short reports targeting the stock [8] - Geron Corporation shares decreased by 31% to $1.6250 following its quarterly results [8] Economic Indicators - U.S. mortgage applications declined by 1.2% for the week ending Feb. 21 [9] - U.S. crude oil inventories fell by 2.332 million barrels, contrary to market expectations of a 2.54 million barrel increase [9] - Sales of new single-family homes in the U.S. decreased by 10.5% to an annualized rate of 657,000 in January [9] - Building permits also declined by 0.6% to an annualized rate of 1.473 million in January [9]

Market Overview - U.S. stocks showed mixed performance with the Nasdaq Composite gaining approximately 150 points, while the Dow decreased by 0.06% to 43,594.06 and the S&P 500 rose by 0.46% to 5,983.30 [1] - Information technology shares increased by 1.4%, while consumer staples shares fell by 1.6% [1] Company Earnings - Lowe's Companies, Inc. reported fourth-quarter adjusted earnings per share of $1.93, exceeding the expected $1.84, with quarterly sales of $18.553 billion, a slight decline of 0.3% year-over-year but above the analyst consensus of $18.292 billion [2] - For 2025, Lowe's projects EPS between $12.15 and $12.40, which is below the consensus estimate of $12.51, and total sales are expected to be between $83.5 billion and $84.5 billion, compared to the consensus of $84.56 billion [3] Stock Movements - Enveric Biosciences, Inc. saw its shares surge by 108% to $2.4540 following positive news regarding its non-hallucinogenic psychedelic compounds [8] - Mullen Automotive, Inc. shares increased by 72% to $4.0685 after its vehicles were added to a government purchasing contract [8] - Porch Group, Inc. shares rose by 65% to $6.25 after reporting fourth-quarter financial results [8] - Flywire Corporation's shares dropped by 41% to $10.48 due to worse-than-expected fourth-quarter results [8] - Venus Concept Inc. shares fell by 34% to $0.3540 following several senior management changes [8] - Geron Corporation's shares decreased by 31% to $1.64 after posting quarterly results [8]